{"slug":"latency","tag":"latency","variants":["latency"],"description":"No description yet","count":2,"kinds":{"bottleneck":1,"idea":1},"related":[{"slug":"open-problem","tag":"open-problem","shared":2},{"slug":"rejuvenation","tag":"rejuvenation","shared":2},{"slug":"second-cancers","tag":"second-cancers","shared":2},{"slug":"survivorship","tag":"survivorship","shared":2}],"records":[{"id":"rejuv-agenda-latency-outruns-the-evidence","kind":"bottleneck","name":"The newest treatments have not existed long enough for their late effects to appear","route":"/bottlenecks/rejuv-agenda-latency-outruns-the-evidence/","tldr":"A second cancer after radiotherapy can take forty years to appear. Immunotherapy and antibody-drug conjugates have been in first-line use for a few. Being told a new drug has no late effects usually means nobody has been followed long enough to see one."},{"id":"idea-rejuv-second-cancer-latency-cohort-for-new-drugs","kind":"idea","name":"Enrol every new systemic therapy into a registry linkage that will still report in thirty years","route":"/ideas/idea-rejuv-second-cancer-latency-cohort-for-new-drugs/","tldr":"A second cancer after radiotherapy can take forty years to appear. Checkpoint inhibitors and antibody-drug conjugates have been in first-line use for a few, so nobody can say anything about their late effects, and nobody is building the thing that could."}]}